TY  - JOUR
A1  - Trinks, Nora
A1  - Reinhard, Sebastian
A1  - Drobny, Matthias
A1  - Heilig, Linda
A1  - Löffler, Jürgen
A1  - Sauer, Markus
A1  - Terpitz, Ulrich
T1  - Subdiffraction-resolution fluorescence imaging of immunological synapse formation between NK cells and A. fumigatus by expansion microscopy
JF  - Communications Biology
N2  - Expansion microscopy (ExM) enables super-resolution fluorescence imaging on standard microscopes by physical expansion of the sample. However, the investigation of interactions between different organisms such as mammalian and fungal cells by ExM remains challenging because different cell types require different expansion protocols to ensure identical, ideally isotropic expansion of both partners. Here, we introduce an ExM method that enables super-resolved visualization of the interaction between NK cells and Aspergillus fumigatus hyphae. 4-fold expansion in combination with confocal fluorescence imaging allows us to resolve details of cytoskeleton rearrangement as well as NK cells' lytic granules triggered by contact with an RFP-expressing A. fumigatus strain. In particular, subdiffraction-resolution images show polarized degranulation upon contact formation and the presence of LAMP1 surrounding perforin at the NK cell-surface post degranulation. Our data demonstrate that optimized ExM protocols enable the investigation of immunological synapse formation between two different species with so far unmatched spatial resolution.
KW  - biological fluorescence
KW  - fluorescence imaging
KW  - imaging the immune system
KW  - infectious diseases
KW  - super-resolution microscopy
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-264996
VL  - 4
IS  - 1
ER  - 
TY  - JOUR
A1  - Seif, Michelle
A1  - Einsele, Hermann
A1  - Löffler, Jürgen
T1  - CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases
JF  - Frontiers in Immunology
N2  - Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.
KW  - infectious diseases
KW  - mAb engineering
KW  - CAR T cells
KW  - HIV
KW  - HCV
KW  - CMV
KW  - invasive aspergillosis
KW  - HBV
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195596
SN  - 1664-3224
VL  - 10
IS  - 2711
ER  -